18:55 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
18:49 , Jul 5, 2018 |  BC Extra  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
14:55 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) on June 25, marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut...
22:02 , Jun 25, 2018 |  BC Extra  |  Company News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH), marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut syndrome and Dravet...
16:32 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Panel: risk/benefit favorable for GW Epidiolex

An FDA advisory committee voted 13-0 that the benefit-risk profile of Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) was favorable to treat seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome ages two years and...
20:43 , Apr 19, 2018 |  BC Extra  |  Company News

Panel: Risk/benefit favorable for GW's Epidiolex

An FDA advisory committee voted 13-0 on Thursday that the benefit-risk profile of Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) was favorable to treat seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome ages 2...
19:30 , Apr 17, 2018 |  BC Extra  |  Company News

GW posts gain ahead of Epidiolex panel

GW Pharmaceuticals plc (NASDAQ:GWPH) climbed $13.55 (11%) to $134.13 on Tuesday after FDA released briefing documents ahead of an advisory committee's planned April 19 meeting concerning an NDA for Epidiolex cannabidiol to treat Lennox-Gastaut syndrome...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...